The latest from Velocity Clinical Research

Video: Scale for a Purpose

January 3, 2024

A staggering 80% of clinical trials are delayed or shut down due to enrollment challenges, with half of those delays occurring at the site level. Two-thirds of principal investigators leave research after conducting a single trial. It’s time for a change. Watch Paul Evans, … Read more

Velocity Expands to 17 Sites in Europe

January 3, 2024

Velocity Clinical Research, the leading multi-specialty clinical sites organization, today announces its further expansion in Europe, adding five sites in Poland after acquiring multi-site network KO-MED Centra Kliniczne and two in Germany, having acquired The Pulmonary Research Institute at the LungenClinic Grosshansdorf and KLB … Read more

Velocity Supported Clinical Trials That Led to 12 Product Approvals in 2023

December 27, 2023

Velocity has made an incredible impact over the past year! Our sites conducted clinical trials that supported 12 U.S. product approvals in 2023, contributing to the betterment of global health. To date, Velocity has contributed to research programs for over 50 product approvals. From … Read more

Removing Language as a Barrier for Clinical Trial Participants

December 19, 2023

Velocity Clinical Research is committed to inclusivity and ensuring that everyone, regardless of their nationality or spoken language, can participate in groundbreaking clinical research studies. Language should never be a barrier to advancing medicine, and so, in collaboration with Boostlingo, we offer live phone … Read more

Velocity Clinical Research Expands to Poland

December 6, 2023

Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has expanded into Poland, acquiring its first site, ClinMedica Research. Located in Skierniewice, which is halfway between Warsaw and Lodz, the site marks the first in a series of key acquisitions targeted by … Read more

Julio Rosenstock, MD, FACE Featured on ADA Diabetes Core Update Podcast

November 30, 2023

Julio Rosenstock, MD, FACE, joined the American Diabetes Association’s Diabetes Core Update podcast to discuss propound results from a recently published JAMA article, “Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes.” The study indicated that once weekly tirzepatide with insulin … Read more

PI Savors Opportunity to Advance Medicine

November 21, 2023

“Without clinical research, there would be little if any development of new medicines,” says Isabelle Schenkenberger, MD. “I’m proud and excited to be a part of it.”  Dr. Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new … Read more

Kris Kowdley, MD, Lead Author Published in NEJM Article

November 20, 2023

Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, is the lead author of an article recently published in the New England Journal of Medicine. The article highlights the results of a Phase 3 trial of elafibranor for the treatment primary biliary cholangitis, an autoimmune disease … Read more

Velocity Announces New MASH CARE Council

November 2, 2023

Velocity is proud to announce the MASH Council to Accelerate Research Excellence (CARE). Led by Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, the MASH CARE Council will help drive world-class operational, recruitment, and trial conduct oversight for the 20+ … Read more

Paul Evans Named CEO of the Year by Business North Carolina

November 1, 2023

Paul Evans was recently named CEO of the Year in the Middle Market Division by Business North Carolina! He, along with his fellow awardees in the Enterprise and Growth categories, were celebrated last month at the annual CEO Summit. Since moving to North Carolina … Read more

Kris Kowdley, MD, Velocity PI, Lead Author of Article Published in The Lancet Gastroenterology & Hepatology

October 27, 2023
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, Principal Investigator at Velocity Lead Author, Article Published in The Lancet Gastroenterology & Hepatology

Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, was the lead author of an article recently published in The Lancet Gastroenterology & Hepatology. Dr. Kowdley and team conducted a Phase 2 trial investigating the efficacy of rusfertide in treating HFE-related haemochromatosis (an inherited iron overload … Read more

Velocity Aggressively Expands MASH/MASLD Capabilities with Latest Site Acquisitions

October 25, 2023
Velocity Expands MASH/MASLD Capabilities With New Sites in Seattle, WA, and Waco, TX

Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD … Read more

Learn more about Velocity's capabilities

Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.

Join a remarkable team doing remarkable work

Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.

Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.

Quality. Continuity. Velocity.